Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP
Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP
复制标题
DOI：
10.3109/10428199809057618
复制
发表时间：
1998-11-01
影响因子：
2.6
通讯作者：
Bernengo, MG
中科院分区：
文献类型：
--
作者：
Fierro, MT;Quaglino, P;Bernengo, MG
全身多药化疗治疗原发性皮肤b细胞淋巴瘤（CBCL）或t细胞淋巴瘤（CTCL）的疗效仍存在争议。81例患者（46例原发性CBCL和35例CTCL）接受COP或CHOP方案治疗。在原发性CBCL中，总体客观缓解率（RR）为98%，CR率为89%，复发率为33%。5年无病生存率为70%，5年生存率为97%。腿部或广泛病变患者的复发率（55%比26%）高于躯干或头部病变患者。CTCL患者的总体目标RR为40%，CR率为23%；中位缓解持续时间为5.7个月，中位生存期为19个月。结果证实原发性CBCL预后良好，并证实了政策血液治疗的有效性。CHOP方案优于COP方案，因为它可以减少复发率。相反，在CTCL患者中，没有使用COP/CHOP方案作为一线化疗的适应症。
The efficacy of systemic polychemotherapy in the treatment of primary cutaneous B-cell lymphomas (CBCL) or T-cell lymphomas (CTCL) is still controversial. A series of 81 patients (46 primary CBCL and 35 CTCL) were treated with COP or CHOP regimens. In primary CBCL, the overall objective response rate (RR) was 98 %, with an 89 % CR rate and a 33 % relapse-rate. Five-year disease-free survival was 70 %, 5-year survival 97 %. Patients with leg or widespread lesions showed a higher relapse-rate (55 % vs 26 %) than those with trunk or head lesions. The overall objective RR was 40 % in CTCL patients, with a 23 % CR rate; median response duration was 5.7 months, median survival 19 months. The results confirm both the good prognosis of primary CBCL and the efficacy of polichemotherapy. CHOP regimen is to be preferred to COP in as much as it reduces relapse rates. Conversely, there are no indications for the use of COP/CHOP regimens as first-line chemotherapy in CTCL patients.